In a groundbreaking achievement, Insilico Medicine has developed the world’s first fully AI-generated drug for idiopathic pulmonary fibrosis (IPF) that just recently positively underwent stage 2 clinical trials. Using an innovative AI platform, the drug reached clinical trials in record time, showing significant improvement in lung function within 12 weeks. This breakthrough could revolutionize drug discovery for many untreatable diseases including cancer.
